Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Phase 2

Completed

• Conditions: Schizophrenia; Bipolar I Disorder; Bipolar II Disorder; Mood Disorder NOS; Severe Major Depression With Psychotic Features; Single Episode Major Depression Without Psychotic Symptoms; Severe Mood Disorder With Psychotic Features; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS
• Interventions: Drug: Latuda©

• Registration Number: NCT01731119
• Lead Sponsor: University of North Carolina, Chapel Hill

Brief Summary

The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform decisions about including a lurasidone arm in a future large scale trial of different approaches to minimize antipsychotic associated weight gain in the pediatric population. In adults, lurasidone appears to cause minimal weight gain. The participants will be 6-19 years old with psychotic spectrum, mood spectrum, or autism spectrum disorders. They will have 4 weeks or less of lifetime antipsychotic exposure.

Detailed Description

This is a multi-site, 12-week, open-label study assessing the weight and metabolic changes associated with lurasidone treatment. Antipsychotic (AP) naive subjects will start open-label treatment by following a flexible titration schedule. Quasi-antipsychotic naive subjects (less than 4 weeks of total AP treatment) will be started on lurasidone and tapered off the other antipsychotic over an estimated 4 weeks depending on the dose and tolerability of the prior antipsychotic. Other psychoactive medications including antidepressants, benzodiazepines, stimulants, alpha-2 agonists, and mood stabilizers are allowed as long as the dose is not changed, unless it is clinically necessary. Assessments of weight, efficacy, and side effects are conducted at baseline, week 2, week 4, week 8, and week 12. The primary outcome is percent change in weight. The secondary outcomes include psychiatric efficacy measures and side effects.

Study Timeline

• Study First Submitted: 2012-11-14
• Study First Submitted QC: 2012-11-20
• Study First Posted: 2012-11-21
• Study Start: 2012-12
• Primary Completion: 2014-08
• Study Completion: 2014-08
• Results First Submitted: 2017-02-23
• Status Verified: 2017-04
• Results First Submitted QC: 2017-04-11
• Results First Posted: 2017-05-17
• Last Update Submitted: 2017-05-18
• Last Update Posted: 2017-06-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 9

Inclusion Criteria

• Male and female children and adolescents between 6 and 19 years of age of any race or ethnicity

• Subject must meet Diagnostic Statistical Manual (DSM)-IV-Text Revision (TR) criteria for a psychotic spectrum, mood spectrum or autism spectrum disorder as defined by one of the following diagnoses:

  • schizophrenia (any type)
  • schizoaffective disorder
  • schizophreniform disorder
  • psychosis Not Otherwise Specified (NOS)
  • autistic disorder with significant irritability/aggression (Aberrant Behavioral Checklist-Community (ABC-C) Irritability subscale score of greater than or equal to 18)
  • Asperger syndrome with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18)
  • pervasive developmental disorder NOS with significant irritability/aggression (ABC-C Irritability subscale score of greater than or equal to 18)
  • bipolar type I
  • bipolar type II
  • mood disorder NOS
  • major depression with psychotic features
  • major depression (unresponsive to 2 different antidepressants)
  • severe mood dysregulation (SMD) according to Leibenluft and colleagues broad spectrum bipolar disorder

• Subjects must have ≤ 4 weeks of lifetime exposure to an antipsychotic medication at any dosage. These medications include olanzapine (Zyprexa©), quetiapine (Seroquel©), risperidone (Risperdal©), ziprasidone (Geodon©), aripiprazole (Abilify©), asenapine (Saphris©), iloperidone (Fanapt©), lurasidone (Latuda©), haloperidol, chlorpromazine, perphenazine, fluphenazine, thiothixene, or clozapine

• Subjects on other psychoactive medications are asked not to change dose of those medications during the course of the study unless clinically necessary

• Sexually active girls must agree to use two effective forms of birth control (i.e. hormonal or spermicidal and barrier) or be abstinent)

• Primary caretaker is able to participate in study appointments as is clinically indicated

• Ability of child to participate in all aspects of the protocol per investigator's clinical judgment

• After considering all aspects of study participation the subject (if an adult) or subject's parent or Legally Authorized Representative (LAR) must consent to participation

• After considering all aspects of study participation, the subject must assent to participation if it is developmentally appropriate to obtain assent

Read More

Exclusion Criteria

• Based on current or lifetime DSM-IV-TR criteria, a diagnosis of Eating Disorder (Anorexia Nervosa or Bulimia Nervosa)
• Based on DSM-IV-TR criteria, a diagnosis of Substance Dependence Disorder (other than tobacco dependence) within the past month
• Treatment with the following concomitant medications: strong CYP3A4 inhibitors (ex: Ketoconazole), strong CYP3A4 inducers (ex: Rifampin)
• Current or past treatment with lurasidone (Latuda©) that resulted in a non-response or intolerance
• Females who are pregnant or breast-feeding
• Ongoing or previously undisclosed child abuse requiring new department of social service intervention
• Subjects who, in the Investigator's opinion, might not be suitable for the study

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Flexible Dose Latuda©	Latuda©	Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.

Primary Outcome Measures

Name	Time	Method
Change in Weight	Baseline to 12 weeks	Change in weight from Baseline to Week 12 will be assessed as the primary outcome measure. Subjects will be asked to step on a special scale called a tanita which will calculate weight, fat mass at each study visit.

Secondary Outcome Measures

Name	Time	Method
Changes in Efficacy Measures	Baseline to 12 weeks	Efficacy measures included the Aberrant Behavior Checklist-Community (ABC-C) total score which focuses on problem behaviors in five subdomains, including irritability, attention, repetitive behaviors, unusual speech, and social withdrawal. Differences in subdomains were not assessed. The ABC-C total score is the sum of 58 items, each rated among 0 = Not at all; 1 = Slight in degree; 2 = Moderately serious; and 3 = Severe in degree. The ABC-C total score ranges from 0 to 174. Higher values of ABC-C total scores represent greater severity of illness.
Number of Participants Experiencing Side Effects	Baseline to12 weeks	Assessment of the medication side effects associated with lurasidone (Latuda©) in children and adolescents.
Proportion of Participants Completing Treatment	12 weeks	Data will be collected on why participants terminated the study. If terminated early, the specific reason will be collected such as efficacy or tolerability.
Overall Clinical Improvement	Baseline to 12 weeks	Overall psychiatric functioning will be assessed with the improvement (CGI-I) subscales of the CGI. CGI-I items are rated from 1 (very much improved) to 7 (very much worse).

Trial Locations

Locations (1)

University of North Carolina; 🇺🇸 Chapel Hill, North Carolina, United States